We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+26.76%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.78B
AUM Growth
+$199M
Cap. Flow
-$18.8M
Cap. Flow %
-1.06%
Top 10 Hldgs %
47.19%
Holding
82
New
6
Increased
3
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$38.6M
2
VERU icon
Veru
VERU
+$36.1M
3
EXEL icon
Exelixis
EXEL
+$24.2M
4
VTYX
Ventyx Biosciences
VTYX
+$18.8M
5
GOSS icon
Gossamer Bio
GOSS
+$13.8M

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$42.9M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$37.1M
3
BPMC
Blueprint Medicines
BPMC
+$14.9M
4
BMEA icon
Biomea Fusion
BMEA
+$14.2M
5
NUVB icon
Nuvation Bio
NUVB
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.33%
2 Financials 0.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAC icon
51
Cartesian Therapeutics
RNAC
$229M
$5.39M 0.3%
109,469
– –
BCAB icon
52
BioAtla
BCAB
$5.46M
$5.29M 0.3%
13,727
– –
THRX
53
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$5.17M 0.29%
892,057
– –
CNTA
54
DELISTED
Centessa Pharmaceuticals
CNTA
$5.03M 0.28%
1,251,137
– –
BLSA
55
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$5.01M 0.28%
500,000
– –
EQRX
56
DELISTED
EQRx, Inc. Common Stock
EQRX
$4.95M 0.28%
1,000,000
– –
PANA
57
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$4.9M 0.28%
500,000
– –
OBIO icon
58
Orchestra BioMed
OBIO
$238M
$3.96M 0.22%
400,000
– –
DBVT
59
DBV Technologies
DBVT
$799M
$3.78M 0.21%
213,460
– –
BCEL
60
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$3.46M 0.19%
2,202,333
– –
BDTX icon
61
Black Diamond Therapeutics
BDTX
$96.8M
$3.4M 0.19%
2,014,858
– –
ORIC icon
62
Oric Pharmaceuticals
ORIC
$1.15B
$3.37M 0.19%
1,054,000
– –
TCRT icon
63
Alaunos Therapeutics
TCRT
$4.59M
$2.58M 0.15%
+10,000
New +$2.9M
IRON icon
64
Disc Medicine
IRON
$2.96B
$2.13M 0.12%
43,333
– –
OMEG
65
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$1.99M 0.11%
200,000
– –
MREO
66
Mereo BioPharma
MREO
$54.7M
$1.94M 0.11%
2,250,000
– –
LITS
67
Lite Strategy Inc
LITS
$32.8M
$1.13M 0.06%
145,655
– –
TARA icon
68
Protara Therapeutics
TARA
$220M
$619K 0.03%
209,227
– –
CDAK
69
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$382K 0.02%
488,157
-361,908
-43% -$760K
CABA icon
70
Cabaletta Bio
CABA
$437M
$351K 0.02%
540,000
– –
BLCM
71
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$68K ﹤0.01%
56,950
– –
NUVB.WS
72
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$45K ﹤0.01%
266,666
– –
SRZNW icon
73
Surrozen Inc Warrant
SRZNW
$11K ﹤0.01%
66,666
– –
ALGS icon
74
Aligos Therapeutics
ALGS
$26.2M
– –
-61,042
Closed -$1.85M
BMEA icon
75
Biomea Fusion
BMEA
$84.6M
– –
-1,188,405
Closed -$14.2M
1 2
3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Boxer Capital held 82 positions worth $1.78B, up 13% from $1.58B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Boxer Capital's Q3 2022 filing shows 6 new, 3 increased, 8 reduced and 9 closed positions. Its largest new stake was Veru: 250,000 shares worth $28.8M. The largest sale was Turning Point Therapeutics, Inc. Common Stock, an estimated $42.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q3 2022 buy was Veru: 250,000 shares worth $28.8M.
  • Boxer Capital added most to SpringWorks Therapeutics in Q3 2022, an estimated $38.6M increase.
  • Boxer Capital's biggest Q3 2022 reduction was Blueprint Medicines, cutting an estimated $14.9M.
  • Boxer Capital fully exited Turning Point Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $42.9M.
  • Boxer Capital's ten largest holdings make up 47% of its $1.78B portfolio in Q3 2022.
  • Boxer Capital opened 6 new positions and closed 9 in Q3 2022.
  • Boxer Capital's portfolio value rose 13% quarter-over-quarter to $1.78B.

Based on Boxer Capital's 13F filing for Q3 2022, filed 14 Nov 2022.